Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

About

The Clinical BioManufacturing Facility is the University of Oxford’s GMP (Good Manufacturing Practice) manufacturing facility.

The Clinical BioManufacturing Facility has over 20 years experience producing biological Investigational Medicinal Products (IMPs) according to the principles of GMP for early phase clinical trials. We hold a Manufacturer’s Authorisation for Investigational Medicinal Products (MIA (IMPs)) from the Medicines and Healthcare products Regulatory Agency (MHRA), which allows us to manufacture a variety of products including viral vector and recombinant protein vaccines and advanced therapy medicinal products (ATMPs) such as cell and gene therapy products. All IMPs are manufactured and released in accordance with the European Clinical Trials Directive (2004). The facility can also import IMPs from outside the EU for use in clinical trials within the European Union.

We aim to provide the link between academic research and clinical drug development, to allow all our collaborators to make rapid progress into clinical trials.

Our GMP manufacturing facility enables us to meet the special demands for phase I/II clinical trials of novel biotech products within the academic and commercial sectors and to deliver effective short term treatments to the clinic providing long term benefits to the patient.

News

Study reveals high number of persistent COVID-19 infections in the general population

A new study – led by researchers at PSI – has found that a high proportion of SARS-CoV-2 infections in the general population lead to persistent infections lasting a month or more. The findings have been published today in the journal Nature.

Abstract submission deadline extended: International Pandemic Sciences Conference 2024

The deadline for abstract submissions and bursary applications for the International Pandemic Sciences Conference 2024 – Collaboration Beyond Boundaries has been extended to Monday 26 February 2024.

Students explore 'wicked problem' of pandemics

Students on the MSc International Health and Tropical Medicine programme discussed pandemics, during a day exploring some of the major challenges in global health, hosted by PSI's Dr Alice Norton.

Follow NDM